Camurus AB

CAMX

SE0007692850

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 11:08:34 28/06/2024 BST			5-day change	1st Jan Change
600 ^SEK	+1.10%		+2.65%	+11.43%

06-25	Camurus Announces the Publication in JAMA Network Open of A New Post H Holes Analysis from A 24-Week Randomized, Double-Blind, Phase 3 Study	CI
05-23	Camurus' Rare Growth Disorder Drug Accepted for Review in EU	MT

Camurus AB Provides Earnings Guidance for the Year 2021

July 15, 2021 at 06:00 am

Camurus AB (publ) provided earnings guidance for the year 2021. For the year, the company expects total revenue to be in the range of SEK 680 million to SEK 750 million and operating loss of SEK 120 million.

Latest news about Camurus AB

Camurus Announces the Publication in JAMA Network Open of A New Post H Holes Analysis from A 24-Week Randomized, Double-Blind, Phase 3 Study	06-25	CI
Camurus' Rare Growth Disorder Drug Accepted for Review in EU	05-23	MT
Camurus Receives EMA Acceptance of MAA Filing for Octreotide SC Depot for the Treatment of Acromegaly	05-23	CI
Transcript : Camurus AB, Q1 2024 Earnings Call, May 08, 2024	05-08
Camurus AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Certain Shares of Camurus AB are subject to a Lock-Up Agreement Ending on 17-APR-2024.	04-16	CI
Camurus AB Announces Board Resignations	04-02	CI
Camurus' New Drug Application for Acromegaly Treatment Accepted by US FDA	03-05	MT
Camurus AB Announces FDA Acceptance of NDA Submission for Oclaiz? for Treatment of Acromegaly	03-05	CI
Camurus AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-15	CI
Nordic Shares Rose Thursday; Tomra Systems Climbed Highest	02-15	DJ
Transcript : Camurus AB, 2023 Earnings Call, Feb 15, 2024	02-15
Camurus AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-15	CI
Camurus AB Provides Earnings Guidance for the Full Year 2024	02-15	CI
Camurus AB Appoints Behshad Sheldon as President of Camurus Inc. and Member of the it's Executive Management Team, Starting 1 April 2024	02-13	CI
Camurus AB Completes Enrollment in the POSITANO Study of CAM2029 in Patients with Polycystic Liver Disease	02-08	CI
Nordic Stocks Rose Thursday; Kinnevik Series B Topped Leaders	01-18	DJ
Nordic Shares Rose Wednesday; Filo Climbed Highest	01-10	DJ
Camurus Submits US FDA New Drug Application for Hormonal Disorder Treatment	12-21	MT
Camurus AB Submits New Drug Application to the US FDA for Oclaiz for Treatment of Acromegaly	12-21	CI
Camurus to Trade on Nasdaq Stockholm's Large Cap Segment	12-20	MT
Camurus Concludes Enrollment in Phase 3 Study of Neuroendocrine Tumors Vaccine	12-14	MT
Camurus AB Announces Completed Enrollment in the Phase 3 SORENTO Study of CAM2029 in Patients with Neuroendocrine Tumors	12-14	CI
Nordic Stocks Decreased Thursday; Okeanis Eco Tankers Took Biggest Hit	11-09	DJ
Transcript : Camurus AB, Q3 2023 Earnings Call, Nov 09, 2023	11-09

Chart Camurus AB

Duration

Period

More charts

Company Profile

Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Companyâs products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.

Sector

Pharmaceuticals

Calendar

15/07/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Camurus AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

593.5 SEK

Average target price

621.5 SEK

Spread / Average Target

+4.72%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CAMURUS AB	+11.43%	3.28B
ELI LILLY AND COMPANY	+55.95%	819B
NOVO NORDISK A/S	+43.16%	638B
JOHNSON & JOHNSON	-6.98%	351B
MERCK & CO., INC.	+19.08%	329B
ABBVIE INC.	+9.05%	298B
ASTRAZENECA PLC	+17.11%	242B
ROCHE HOLDING AG	+2.54%	225B
NOVARTIS AG	+13.22%	217B
AMGEN INC.	+8.91%	168B

Other Pharmaceuticals

Camurus AB

Equities

CAMX

SE0007692850

Pharmaceuticals

Camurus AB Provides Earnings Guidance for the Year 2021

EPS Revisions